Zobrazeno 1 - 10
of 184
pro vyhledávání: '"Shaji K, Kumar"'
Autor:
Matteo Giaccherini, Alyssa I. Clay-Gilmour, Romano Liotti, Angelica Macauda, Manuel Gentiluomo, Elizabeth E. Brown, Mitchell J. Machiela, Stephen J. Chanock, Michelle A. T. Hildebrandt, Aaron D. Norman, Elisabet Manasanch, S. Vincent Rajkumar, Jonathan N. Hofmann, Sonja I. Berndt, Parveen Bhatti, Graham G. Giles, Elad Ziv, Shaji K. Kumar, Nicola J. Camp, Wendy Cozen, Susan L. Slager, Federico Canzian, Federica Gemignani, Celine M. Vachon, Daniele Campa
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/80466d49fbbd467887abb1da0f10e198
Autor:
Surbhi Sidana, Andriyana K. Bankova, Hitomi Hosoya, Shaji K. Kumar, Tyson H. Holmes, John Tamaresis, Anne Le, Lori S. Muffly, Sofia Maysel-Auslender, Laura Johnston, Sally Arai, Robert Lowsky, Everett Meyer, Andrew Rezvani, Wen-Kai Weng, Matthew J. Frank, Parveen Shiraz, Holden T. Maecker, Ying Lu, David B. Miklos, Judith A. Shizuru
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract MGTA-145 or GROβT, a CXCR2 agonist, has shown promising activity for hematopoietic stem cell (HSC) mobilization with plerixafor in pre-clinical studies and healthy volunteers. Twenty-five patients with multiple myeloma enrolled in a phase 2
Externí odkaz:
https://doaj.org/article/c4ea76784f8e439895fbf960f62bde47
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/f565a34e20224330a6314730dd053ece
Autor:
Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castaneda Puglianini, Oren Pasvolsky, Rebecca Gonzalez, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, James A. Davis, Megan Herr, Hamza Hashmi, Peter Forsberg, Douglas Sborov, Larry D. Anderson Jr, Joseph P. McGuirk, Charlotte Wagner, Alex Lieberman-Cribbin, Adriana Rossi, Ciara L. Freeman, Frederick L. Locke, Shambavi Richard, Jack Khouri, Yi Lin, Krina K. Patel, Shaji K. Kumar, Doris K. Hansen
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-11 (2024)
Abstract Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel in patients with extramedullary disease (EMD) remain
Externí odkaz:
https://doaj.org/article/681de79c8e1349a19906516ee568e2af
Autor:
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K. Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A. Gertz, Wilson I. Gonsalves, Suzanne R. Hayman, Miriam A. Hobbs, Yi L. Hwa, Taxiarchis Kourelis, Martha Q. Lacy, Nelson Leung, Yi Lin, Rahma M. Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-6 (2024)
Abstract Refractoriness to lenalidomide is an important factor determining the choice of therapy at first relapse in multiple myeloma (MM). It remains debatable if resistance to lenalidomide varies among MM refractory to standard doses vs low dose ma
Externí odkaz:
https://doaj.org/article/eba49be384594a6b9736e10c9aa74562
Autor:
Nadine H. Abdallah, Arjun Lakshman, Shaji K. Kumar, Joselle Cook, Moritz Binder, Prashant Kapoor, Angela Dispenzieri, Morie A. Gertz, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, David Dingli, Yi Lin, Taxiarchis Kourelis, Rahma Warsame, Leif Bergsagel, S. Vincent Rajkumar
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-def
Externí odkaz:
https://doaj.org/article/0c829e27d7424164a3db5cbae0cc8d91
Autor:
Dragan Jevremovic, Min Shi, Pedro Horna, Gregory E. Otteson, Michael M. Timm, Linda B. Baughn, Patricia T. Greipp, Wilson I. Gonsalves, Prashant Kapoor, Morie A. Gertz, Moritz Binder, Francis K. Buadi, Jiehao Zhou, Angela Dispenzieri, Taxiarchis Kourelis, Eli Muchtar, S. Vincent Rajkumar, Shaji K. Kumar, Horatiu Olteanu
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/1952c5e6d543410abc4634a55573e287
Autor:
Nadine H. Abdallah, Hiroki Nagayama, Naoki Takahashi, Wilson Gonsalves, Amie Fonder, Angela Dispenzieri, David Dingli, Francis K. Buadi, Martha Q. Lacy, Miriam Hobbs, Morie A. Gertz, Moritz Binder, Prashant Kapoor, Rahma Warsame, Suzanne R. Hayman, Taxiarchis Kourelis, Yi L. Hwa, Yi Lin, Robert A. Kyle, S. Vincent Rajkumar, Stephen M. Broski, Shaji K. Kumar
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract Measures of muscle and adipose tissue mass have been associated with outcomes in several malignancies, but studies in multiple myeloma (MM) are inconsistent. The aim of this study was to evaluate the association between muscle and fat areas
Externí odkaz:
https://doaj.org/article/38f526e32a8b47e4b2ebfc033e381593
Autor:
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K. Buadi, Joselle Cook, David Dingli, Angela Dispenzieri, Amie L. Fonder, Morie A. Gertz, Wilson Gonsalves, Suzanne R. Hayman, Miriam A. Hobbs, Yi L. Hwa, Taxiarchis Kourelis, Martha Q. Lacy, Nelson Leung, Yi Lin, Rahma Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-4 (2023)
Externí odkaz:
https://doaj.org/article/c837461b72b04beb8b1245eafa6f612b
Autor:
Paul G. Richardson, Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner, Darrell White, Lionel Karlin, Lotfi Benboubker, Eric Voog, Sung‐Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Miguel Villarreal, Philip Twumasi‐Ankrah, Richard Labotka, Robert M. Rifkin, Sagar Lonial, Shaji K. Kumar, S. Vincent Rajkumar, Philippe Moreau
Publikováno v:
eJHaem, Vol 4, Iss 4, Pp 995-1005 (2023)
Abstract Deeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression‐free survival (PFS) and duration of response (DOR) by re
Externí odkaz:
https://doaj.org/article/889b8a2ac5cb4c9cba095e412d3f7b15